Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Heitner

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
European Journal of Heart Failure|March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
JAMA|July 19, 2022
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical TrialGregory D Lewis, Adriaan A Voors, Alain Cohen-Solal, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Automated Echocardiographic Detection of Severe Coronary Artery Disease Using Artificial IntelligenceRoss Upton, Angela Mumith, Arian Beqiri, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
European Journal of Heart Failure|March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
JAMA|July 19, 2022
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical TrialGregory D Lewis, Adriaan A Voors, Alain Cohen-Solal, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.
JACC. Cardiovascular Imaging|December 19, 2021
Automated Echocardiographic Detection of Severe Coronary Artery Disease Using Artificial IntelligenceRoss Upton, Angela Mumith, Arian Beqiri, et al.
Pageof 11